Abnormal Cytokine Production by Circulating Monocytes and Dendritic Cells of Myeloid Origin in ART-Treated HIV-1+ Patients Relates to CD4+ T-Cell Recovery and HCV Co-Infection

Almeida, Maria; Cordero, Miguel; Almeida, Julia; Orfao, Alberto
May 2007
Current HIV Research;Jul2007, Vol. 5 Issue 3, p325
Academic Journal
HIV-1 infection is associated with dysregulation of cytokine production by peripheral blood (PB) monocytes and dendritic cells (DC), but controversial results have been reported. We aimed to analyze the effect of antiretroviral therapy (ART) on the in vitro production of inflammatory cytokines by PB-stimulated monocytes and DC of myeloid origin -CD33high+ myeloid DC (mDC) and CD33+/CD14-/dim+/CD16high+ DC- from HIV-1+ patients and its relationship with CD4+ T-cell recovery and co-infection with hepatitis C virus (HCV). In vitro cytokine production was analyzed at the single cell level in 32 HIV-1+ patients, grouped according to the number of CD4+ T-cells/�l in PB (<200 CD4 versus >200 CD4). Patients were tested prior to therapy and at weeks +2, +4, +8, +12 and +52 after ART. Prior to ART, production of IL-6, TNF-a and IL-12 by mDC and of IL-8 and IL-12 by CD16+ DC was significantly increased among >200 CD4 patients. After one year of ART, increased production of IL-8 by monocytes, of TNF-a by mDC and of IL-1�, IL-6 and TNF-a by CD16+ DC was specifically observed among <200 CD4 HIV-1+ individuals showing a high recovery of PB CD4+ T-cell counts. In turn, we found that the significantly reduced percentage of IL-1�, IL-6, IL-8 and TNF-a-producing monocytes and of IL-6 and IL-8-producing mDC and CD16+ DC, as well as the significantly diminished mean amount of IL-6 produced per monocyte, mDC and CD16+ DC and of IL-12 produced per CD16+ DC observed at week +52 for the >200 CD4 patients, were related to the presence of coinfection with HCV. In summary, HIV-1+ individuals show abnormal production of inflammatory cytokines by PB-stimulated monocytes and DC of myeloid origin even after one year of ART, such abnormalities being associated with the degree of recovery of PB CD4+ T-cell counts in more immunocompromised patients and HCV co-infection in more immunocompetent HIV-1+ individuals.


Related Articles

  • Therapeutic Interventions for HIV Infection and Chronic Viral Hepatitis. Cooper, Curtis L. // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS69 

    Combination antiretroviral therapy reduces overall and liver-specific morbidity and mortality in coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and represents the most beneficial pharmaceutical treatment intervention for most coinfected patients. Antiviral...

  • HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. ANDREONI, M.; GIACOMETTI, A.; MAIDA, I.; MERAVIGLIA, P.; RIPAMONTI, D.; SARMATI, L. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 11, p1473 

    Hepatitis C virus (HCV) is the cause of more than three-quarters of liver-related deaths in HIV-seropositive individuals and it is remarkable that today approximately one-quarter of HIV-infected individuals in Europe and the USA have a HCV coinfection. HIV/HCV coinfected patients were more...

  • Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic. Sheng, Wang-Huei; Chen, Mao-Yuan; Hsieh, Szu-Min; Hsiao, Chin-Fu; Wang, Jann-Tay; Hung, Chien-Ching; Chang, Shan-Chwen // Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1471 

    Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV-infected patients without HBV or hepatitis C virus coinfection were prospectively observed to assess the impact of HBV infection...

  • Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV-Coinfected Subjects Treated with Interferon-Based Regimens. Sherman, Kenneth E.; Rouster, Susan D.; Stanford, Sandra; Blackard, Jason T.; Shire, Norah; Koziel, Margaret; Peters, Marion; Chung, Raymond T. // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p712 

    Background. Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has emerged as a major cause of morbidity and mortality due to liver disease. Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between...

  • Influence of Hepatitis C Virus Coinfection on Failure of HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy to Achieve Normal Serum β2Microglobulin Levels. García-García, J. A.; Mira, J. A.; Fernández-Rivera, J.; Ramos, A. J.; Vargas, J.; Macías, J.; Pineda, J. A. // European Journal of Clinical Microbiology & Infectious Diseases;Mar2003, Vol. 22 Issue 3, p194 

    The influence of hepatitis C virus (HCV) coinfection on the kinetics of serum β2microglobulin levels in HIV-infected patients undergoing highly active antiretroviral therapy was analyzed. After 96 weeks of therapy, β2microglobulin levels declined significantly both in 24 HCV seronegative...

  • Drugs to Treat Both HIV, Hepatitis C.  // Guide;Apr2004, Vol. 24 Issue 4, p19 

    Reports that Roche Corp. said a trial of a two-drug combination therapy for HIV-positive persons with hepatitis C virus showed a marked benefit against viral levels. Hepatitis C drug Pegasys and antiviral Copegus; Sustained 40 percent virological response in a trial of 868 patients; Virological...

  • Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. Braitstein, Paula; Yip, Benita; Montessori, Valentina; Moore, David; Montaner, Julio S. G.; Hogg, Robert S. // CMAJ: Canadian Medical Association Journal;7/19/2005, Vol. 173 Issue 2, p160 

    Abstract Background We examined the effect of hepatitis C virus (HCV) seropositivity on risk of death among people receiving their first antiretroviral treatment (ART) for HIV infection. Methods In British Columbia, the HIV/ AIDS Drug Treatment Program is the only source of free ART. Patients...

  • Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Bukowska-Ośko, Iwona; Pawełczyk, Agnieszka; Perlejewski, Karol; Kubisa, Natalia; Caraballo Cortés, Kamila; Rosińska, Magdalena; Płoski, Rafał; Fic, Maria; Kaźmierczak, Justyna; Popiel, Marta; Ząbek, Piotr; Horban, Andrzej; Radkowski, Marek; Laskus, Tomasz // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus...

  • Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection. Saag, Michael S. // JAMA: Journal of the American Medical Association;7/23/2014, Vol. 312 Issue 4, p347 

    An introduction is presented in which the editor discusses microeconomics, quantum leap mechanics, and the treatment of patients with hepatitis C virus (HCV) and HIV coinfection, published in the July 23/30, 2014 issue of the "Journal of American Medical Association" (JAMA).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics